Potentiation of Cytotoxic Therapies by TNP-470 and Minocycline in Mice Bearing EMT-6 Mammary Carcinoma

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1995 Jan 1

PMID 8534870

Citations 16

Authors

B A Teicher

S A Holden

N P Dupuis

Y Kakeji

M Ikebe

Y Emi

D Goff

Affiliations

Soon will be listed here.

Abstract

The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogenic agents alone or in combination did not alter the growth of the tumors. However, their administration along with cyclophosphamide, CDDP, or thiotepa substantially increased the tumor growth delay produced by these cytotoxic therapies in tumors responsive to the drugs--the increase was about 2-fold for TNP-470 and minocycline together. In drug resistant tumors, treatment with the antiangiogenic agents did not reverse drug resistance but did increase the effect of the cytotoxic drugs. Treatment with TNP-470/minocycline also increased the oxygenation of each of the three tumors. Thus, TNP-470/minocycline administration increased the efficacy of fractionated radiation therapy, especially when used along with a perflubron emulsion oxygen delivery agent/carbogen. These results indicate that treatment regimens including therapies directed toward the proliferating normal cells within a tumor mass as well as therapies directed toward the malignant cells can produce improved outcomes.

Citing Articles

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Gupta R, Cristea M, Frankel P, Ruel C, Chen C, Wang Y Cancer Treat Res Commun. 2019; 21:100155.

PMID: 31279962 PMC: 9018111. DOI: 10.1016/j.ctarc.2019.100155.

A Practical Guide to Analyzing Time-Varying Associations between Physical Activity and Affect Using Multilevel Modeling.

Kim J, Marcusson-Clavertz D, Togo F, Park H Comput Math Methods Med. 2018; 2018:8652034.

PMID: 30105083 PMC: 6076963. DOI: 10.1155/2018/8652034.

A momentary biomarker for depressive mood.

Kim J, Nakamura T, Yamamoto Y In Silico Pharmacol. 2016; 4(1):4.

PMID: 26979449 PMC: 4792818. DOI: 10.1186/s40203-016-0017-6.

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

Barker H, Paget J, Khan A, Harrington K Nat Rev Cancer. 2015; 15(7):409-25.

PMID: 26105538 PMC: 4896389. DOI: 10.1038/nrc3958.

Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Goel S, Wong A, Jain R Cold Spring Harb Perspect Med. 2012; 2(3):a006486.

PMID: 22393532 PMC: 3282493. DOI: 10.1101/cshperspect.a006486.

References

Teicher B, Chatterjee D, Liu J, Holden S, Ara G . Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother Pharmacol. 1993; 32(4):315-9. DOI: 10.1007/BF00686178. View

Folkman J, Watson K, Ingber D, Hanahan D . Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989; 339(6219):58-61. DOI: 10.1038/339058a0. View

Holden S, Teicher B, Ha C, Ara G, Herman T . Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents. Biomater Artif Cells Immobilization Biotechnol. 1992; 20(2-4):895-8. DOI: 10.3109/10731199209119736. View

Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar L . AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. 1994; 54(8):2073-6. View

Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D . Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun. 1991; 174(3):1070-6. DOI: 10.1016/0006-291x(91)91529-l. View

Grunt T, Lametschwandtner A, Karrer K, Staindl O . The angioarchitecture of the Lewis lung carcinoma in laboratory mice (a light microscopic and scanning electron microscopic study). Scan Electron Microsc. 1986; (Pt 2):557-73. View

Teicher B, Sotomayor E, Huang Z . Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992; 52(23):6702-4. View

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H . Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990; 348(6301):555-7. DOI: 10.1038/348555a0. View

Ingber D, Madri J, Folkman J . A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology. 1986; 119(4):1768-75. DOI: 10.1210/endo-119-4-1768. View

10.

Riess J . Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs. 1984; 8(1):44-56. DOI: 10.1111/j.1525-1594.1984.tb04243.x. View

11.

Teicher B, Holden S, Ara G, Sotomayor E, Huang Z, Chen Y . Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer. 1994; 57(6):920-5. DOI: 10.1002/ijc.2910570624. View

12.

Teicher B, Rose C . Perfluorochemical emulsions can increase tumor radiosensitivity. Science. 1984; 223(4639):934-6. DOI: 10.1126/science.6695191. View

13.

Teicher B, Rose C . Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res. 1984; 44(10):4285-8. View

14.

Folkman J . What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990; 82(1):4-6. DOI: 10.1093/jnci/82.1.4. View

15.

Yamamoto T, Sudo K, Fujita T . Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res. 1994; 14(1A):1-3. View

16.

Teicher B, Waxman D, Holden S, Wang Y, Clarke L, Alvarez Sotomayor E . Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide. Cancer Res. 1989; 49(18):4996-5001. View

17.

Chatterjee D, Liu C, Northey D, Teicher B . Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol. 1995; 35(5):423-31. DOI: 10.1007/s002800050257. View

18.

Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S . Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983; 221(4612):719-25. DOI: 10.1126/science.6192498. View

19.

Teicher B, Holden S, Ara G, Ha C, Herman T, Northey D . A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. J Cancer Res Clin Oncol. 1992; 118(7):509-14. DOI: 10.1007/BF01225265. View

20.

Folkman J . What is the role of angiogenesis in metastasis from cutaneous melanoma?. Eur J Cancer Clin Oncol. 1987; 23(4):361-3. DOI: 10.1016/0277-5379(87)90370-1. View